臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

关于TAIR
	计画说明

浏览
	典藏机构
	作者
	题名
	日期
	统计图表
	机构即时统计
	学术趋势

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作权
	出版社及期刊政策查询
	TAIR著作权会议记录

相关连结
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"zhong zhe lin"的相关文件

回到依作者浏览
依题名排序	依日期排序

显示项目 26-75 / 125 (共3页)
1 2 3 > >>
每页显示[10|25|50]项目

机构	日期	题名	作者
臺大學術典藏	2022-06-10T06:11:08Z	Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma	Shau W.-Y.; Shao Y.-Y.; Yeh Y.-C.; ZHONG-ZHE LIN; Kuo R.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2022-06-10T06:11:08Z	Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy	ZHONG-ZHE LIN; Hsu C.; Hu F.-C.; Shao Y.-Y.; Chang D.-Y.; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L.
臺大學術典藏	2022-06-10T06:11:07Z	Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems	Shao Y.-Y.; Lu L.-C.; ZHONG-ZHE LIN; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2022-06-10T06:11:07Z	Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer	Shao Y.-Y.; Shau W.-Y.; ZHONG-ZHE LIN; Chen H.-M.; Kuo R.; Yang J.C.-H.; Lai M.-S.
臺大學術典藏	2022-06-10T06:11:06Z	Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma	Lu L.-C.; Shao Y.-Y.; Kuo R.N.C.; ZHONG-ZHE LIN; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2022-06-10T06:11:06Z	The aurora kinases inhibitor VE-465 is a novel treatment for glioblastoma multiforme	Lee P.-Y.; Chen C.-L.; ZHONG-ZHE LIN; Cheng A.-L.; Chen E.I.-T.; Whang-Peng J.; Huang C.-Y.F.
臺大學術典藏	2022-06-10T06:11:06Z	A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy	Shao Y.-Y.; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; ZHONG-ZHE LIN
臺大學術典藏	2022-06-10T06:11:05Z	Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size	ZHONG-ZHE LIN; Shau W.-Y.; Hsu C.; Shao Y.-Y.; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2022-06-10T06:11:05Z	Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer	Shen Y.-C.; Li C.-P.; Yen C.-J.; Hsu C.; Lin Y.-L.; ZHONG-ZHE LIN; Chen L.-T.; Su W.-C.; Chao Y.; Yeh K.-H.; Cheng A.-L.
臺大學術典藏	2022-06-10T06:11:04Z	Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma	Ou D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; ZHONG-ZHE LIN; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Hsu C.; Cheng A.-L.
臺大學術典藏	2022-06-10T06:11:04Z	Type 2 diabetes mellitus is associated with increased mortality in chinese patients receiving curative surgery for colon cancer	Chen K.-H.; Shao Y.-Y.; ZHONG-ZHE LIN; Yeh Y.-C.; Wen-Yi S.; Kuo R.N.; Chen H.-M.; Lai C.-L.; Yeh K.-H.; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2022-06-10T06:11:04Z	Radiosensitization by combining an aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruption	ZHONG-ZHE LIN; Chou C.-H.; Cheng A.-L.; Liu W.-L.; Chia-Hsien Cheng J.
臺大學術典藏	2022-06-10T06:11:03Z	The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia	Kuo H.-Y.; ZHONG-ZHE LIN; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S.
臺大學術典藏	2022-06-10T06:11:03Z	Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma	Liao B.-C.; Shao Y.-Y.; Chen H.-M.; Shau W.-Y.; ZHONG-ZHE LIN; Kuo R.N.; Lai C.-L.; Chen K.-H.; Cheng A.-L.; Yang J.C.-H.; Lai M.-S.
臺大學術典藏	2022-06-10T06:11:02Z	Young patients with colorectal cancer have increased risk of second primary cancers	Liang Y.-H.; Shao Y.-Y.; Chen H.-M.; Lai C.-L.; ZHONG-ZHE LIN; Kuo R.N.; Cheng A.-L.; Yeh K.-H.; Lai M.-S.
臺大學術典藏	2022-06-10T06:11:02Z	Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan	Shao Y.-Y.; Hsu C.-H.; Yeh K.-H.; Chen H.-M.; Yeh Y.-C.; Lai C.-L.; ZHONG-ZHE LIN; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2022-06-10T06:11:01Z	The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases	Chiang Y.; Yang J.C.-H.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; ZHONG-ZHE LIN; Lan K.-H.; Cheng A.-L.; Kuo S.-H.
臺大學術典藏	2022-06-10T06:11:00Z	Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort study	Chen K.-H.; Shao Y.-Y.; Chen H.-M.; Lin Y.-L.; ZHONG-ZHE LIN; Lai M.-S.; Cheng A.-L.; Yeh K.-H.
臺大學術典藏	2022-06-10T06:11:00Z	Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib	Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; ZHONG-ZHE LIN; Lin C.-C.; Yang J.C.H.; Yu C.-J.
臺大學術典藏	2022-06-10T06:11:00Z	Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)	Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; ZHONG-ZHE LIN; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A.
臺大學術典藏	2022-06-10T06:10:59Z	A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma	Qin S.; Chan S.L.; Sukeepaisarnjaroen W.; Han G.; Choo S.P.; Sriuranpong V.; Pan H.; Yau T.; Guo Y.; Chen M.; Ren Z.; Xu J.; Yen C.-J.; ZHONG-ZHE LIN; Manenti L.; Gu Y.; Sun Y.; Tiedt R.; Hao L.; Song W.; Tanwandee T.
臺大學術典藏	2022-06-10T06:10:59Z	Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy	Shao Y.-Y.; Chen B.-B.; Ou D.-L.; ZHONG-ZHE LIN; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C.
臺大學術典藏	2022-06-10T06:10:58Z	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma	Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; ZHONG-ZHE LIN; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2022-06-10T06:10:58Z	Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations	Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; ZHONG-ZHE LIN; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏	2022-06-10T06:10:57Z	Development and validation of nomograms for predicting survival probability of patients with advanced adenocarcinoma in different EGFR mutation status	Chen H.-C.; Tan E.C.-H.; Liao C.-H.; ZHONG-ZHE LIN; Yang M.-C.
臺大學術典藏	2022-06-10T06:10:57Z	Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non�Vsmall-cell lung cancer patients	Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; ZHONG-ZHE LIN; Lin C.-C.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏	2022-06-10T06:10:57Z	Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma	ZHONG-ZHE LIN; Hsu C.; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Wu Y.-M.; Hsu H.-C.; Cheng A.-L.
臺大學術典藏	2022-06-10T06:10:56Z	Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma	Shao Y.-Y.; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; ZHONG-ZHE LIN; Cheng A.-L.; Hsu C.-H.
臺大學術典藏	2022-06-10T06:10:56Z	First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma	Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K.
臺大學術典藏	2022-06-10T06:10:55Z	Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer	Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; ZHONG-ZHE LIN; Lu S.-H.; Yang J.C.-H.; Cheng A.-L.; Kuo S.-H.
臺大學術典藏	2022-06-10T06:10:55Z	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy	ZHONG-ZHE LIN; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C.
臺大學術典藏	2022-06-10T06:10:54Z	Eg5 as a prognostic biomarker and potential therapeutic target for hepatocellular carcinoma	Shao Y.-Y.; Sun N.-Y.; Jeng Y.-M.; Wu Y.-M.; Hsu C.; Hsu C.-H.; Hsu H.-C.; Cheng A.-L.; ZHONG-ZHE LIN
臺大學術典藏	2022-06-10T06:10:54Z	The Short- and Long-term Causal Relationships Between Self-compassion, Trait Mindfulness, Caregiver Stress, and Depressive Symptoms in Family Caregivers of Patients with Lung Cancer	Hsieh C.-C.; ZHONG-ZHE LIN; Ho C.-C.; Yu C.-J.; Chen H.-J.; Chen Y.-W.; Hsiao F.-H.
臺大學術典藏	2022-06-10T06:10:54Z	Trait mindfulness and depressive symptoms in non-small cell lung cancer patients: the mediating roles of quality of life and meaning in life	Hsieh C.-C.; Ho C.-C.; ZHONG-ZHE LIN; Yu C.-J.; Jow G.-M.; Huang F.-Y.; Shih J.-Y.; Hsiao F.-H.
臺大學術典藏	2022-06-10T06:10:53Z	Early changes in dce-mri biomarkers may predict survival outcomes in patients with advanced hepatocellular carcinoma after sorafenib failure: Two prospective phase ii trials	Chen B.-B.; ZHONG-ZHE LIN; Shao Y.-Y.; Hsu C.; Hsu C.-H.; Cheng A.-L.; Liang P.-C.; Shih T.T.-F.
臺大學術典藏	2022-06-10T06:10:53Z	Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma	Chen B.-B.; Shao Y.-Y.; ZHONG-ZHE LIN; Hsu C.-H.; Cheng A.-L.; Hsu C.; Liang P.-C.; Shih T.T.-F.
臺大學術典藏	2022-06-10T06:10:52Z	Revisiting hepatic artery infusion chemotherapy in the treatment of advanced hepatocellular carcinoma	Chen C.-T.; Liu T.-H.; Shao Y.-Y.; Liu K.-L.; Liang P.-C.; ZHONG-ZHE LIN
臺大學術典藏	2022-06-10T06:10:52Z	Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy	Shen Y.-C.; Yeh C.-P.; Jeng Y.-M.; Hsu C.; Hsu C.-H.; ZHONG-ZHE LIN; Shao Y.-Y.; Lu L.-C.; Liu T.-H.; Chen C.-H.; Cheng A.-L.
臺大學術典藏	2022-06-10T06:10:51Z	Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade	Kelley R.K.; Miksad R.; Cicin I.; Chen Y.H.; Kl?mpen H.-J.; Kim S.; ZHONG-ZHE LIN; Youkstetter J.; Hazra S.; Sen S.; Cheng A.-L.; El-Khoueiry A.B.; Meyer T.; Abou-Alfa G.K.
臺大學術典藏	2022-06-10T06:10:51Z	The Long-Term and Mediating Effects of Mindfulness Integrated with Body-Mind-Spirit Group Therapy on Depressive Symptoms and Quality of Life Among Non-small Cell Lung Cancer Patients	Hsiao F.-H.; ZHONG-ZHE LIN; Huang F.-Y.; Lai Y.-M.; Chen Y.-T.; Shih J.-Y.; Ho C.-C.; Yu C.-J.; Hsieh C.-C.
臺大學術典藏	2022-06-10T06:10:50Z	Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma	Shao Y.-Y.; Kuo H.-Y.; Jeng Y.-M.; Wu Y.-M.; Wang H.-P.; Hsu C.; Hsu C.-H.; Hsu H.-C.; Cheng A.-L.; ZHONG-ZHE LIN
臺大學術典藏	2021-08-11T03:46:54Z	Combination of 13-cis retinoic acid and interferon-�\ in the treatment of recurrent or refractory peripheral T-cell lymphoma	Huang C.-L.; ZHONG-ZHE LIN; Su I.-J.; Chao T.-Y.; Tien H.-F.; Chang M.-C.; Huang M.-C.; Kao W.-Y.; Tang J.-L.; Yeh K.-H.; Wang C.-H.; Hsu C.-H.; Liu M.-Y.; Cheng A.-L.
臺大學術典藏	2021-08-11T03:46:53Z	Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma	Lu Y.-S.; Kashida Y.; Kulp S.K.; Wang Y.-C.; Wang D.; Hung J.-H.; Tang M.; ZHONG-ZHE LIN; Chen T.-J.; Cheng A.-L.; Chen C.-S.
臺大學術典藏	2021-08-11T03:46:53Z	Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy	Yang C.-H.; Yu C.-J.; Shih J.-Y.; Chang Y.-C.; Hu F.-C.; Tsai M.-C.; Chen K.-Y.; ZHONG-ZHE LIN; Huang C.-J.; Shun C.-T.; Huang C.-L.; Bean J.; Cheng A.-L.; Pao W.; Yang P.-C.
臺大學術典藏	2021-08-11T03:46:53Z	Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment	ZHONG-ZHE LIN; Hsu C.; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H.
臺大學術典藏	2021-08-11T03:46:52Z	The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma	ZHONG-ZHE LIN; Hsu H.-C.; Hsu C.-H.; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; Kuo S.-H.; Hsu C.; Hu F.-C.; Jeng Y.-M.; Chung Y.; Cheng A.-L.
臺大學術典藏	2021-08-11T03:46:52Z	Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival	Shen Y.-C.; Hu F.-C.; Jeng Y.-M.; Chang Y.-T.; ZHONG-ZHE LIN; Chang M.-C.; Hsu C.; Cheng A.-L.
臺大學術典藏	2021-08-11T03:46:52Z	Sunitinib-induced myxedema coma	Chen S.-Y.; Kao P.-C.; ZHONG-ZHE LIN; Chiang W.-C.; Fang C.-C.
臺大學術典藏	2021-08-11T03:46:52Z	High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy	Perng R.-P.; Yang C.-H.; Chen Y.-M.; Chang G.-C.; Lin M.-C.; Hsieh R.-K.; Chu N.-M.; Lai R.-S.; Su W.-C.; Tsao C.-J.; Hsia T.-C.; Chen H.-C.; Chen C.-H.; Huang M.-S.; Wang J.-L.; Ho M.-L.; Chung C.-Y.; Yu C.-J.; Chang W.-C.; Kuo H.-P.; Yu C.-T.; ZHONG-ZHE LIN; Kao W.-Y.
臺大學術典藏	2021-08-11T03:46:51Z	Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma	Yang S.-H.; ZHONG-ZHE LIN; Kuo S.-H.; Cheng A.-L.

显示项目 26-75 / 125 (共3页)
1 2 3 > >>
每页显示[10|25|50]项目

	English \| 正體中文 \| 简体中文 \| 总笔数 :0
	造访人次 : 51824392 在线人数 : 787 教育部委托研究计画计画执行:国立台湾大学图书馆